EFFICIENT METHOD OF PRION GENE SILENCING IN VITRO AND IN VIVO BY ANTISENSE-OLIGODEOXYNUCLEOTIDES CONJUGATED WITH NEW DIMETHYLAMINOETHYLMETHACRYLATE OLIGOELECTROLITE
DOI: http://dx.doi.org/10.30970/sbi.0503.168
Abstract
The paper presents some issues of utilizing novel polymeric compound for improving antisense-oligonucleotides delivery to mammalian cells. DNA-binding ability of dimethylaminoethylmethacrylate oligoelectrolite was tested. It was estimated that polyDMAEM in concentration less than 5 µg/ml did not induce cytotoxic effects in mouse embryonic fibroblasts and cells of L1210 line and could be used in in vitro studies. The study of polyDMAEM and its complexes with asODNs action on the cellular prion (PrPC) expression level evinced that different immobilized asODNs caused reduction of PrPC content by 70–90% in L1210 cells. It was found that polyDMAEM is able to decrease PrPC content by 40 % in L1210 cells by itself. Possible mechanisms of such influence are discussed. A possibility of successful using asODNs and carrier conjugates for cellular prion gene silencing in rat spleen and intestine is shown. Effects of polyDMAEM action on PrPC content has not been ascertained in vivo.
Keywords
Full Text:
PDF (Українська)References
1. Иванов И. Ф., Ковальский П. А. Цитология, гистология, эмбриология. Москва: Колос, 1976. 447 с. | |
| |
2. Про захист тварин від жорстокого поводження: Закон України. Відомості Верховної Ради України, 2006; 27: 230. | |
| |
3. Стадник В. В., Майор Х. Я. Ізюмова Л. А. Дизайн антисенс-олігодезоксинуклеотидів для інгібування трансляції мРНК гена Prnp. Науково-технічний бюлетень Інституту біології тварин НААН, 2008; 9 (1-2): 62-66. | |
| |
4. Cashman N. R., Loertscher R., Nalbantoglu J. et al. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell, 1990; 61: 185-192. | |
| |
5. Chesebro B. Introduction to the transmissible spongiform encephalopathies or prion diseases. British Medical Bulletin, 2003; 66: 1-20. | |
| |
6. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. Strasburg: Council of Europe, 1986. 52 р. | |
| |
7. Kim B. H., Lee H. G., Choi J. K. et al. The cellular prion protein (PrPC) prevents apoptotic neuronal cell death and mitochondrial dysfunction induced by serum deprivation. Brain Res. Mol. Brain Res, 2004; 124 (1): 40-50. | |
| |
8. Laemmli U. K. Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4. Nature, 1970; 277(5259): 680-685. | |
| |
9. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent . J. Biol. Chem, 1951; 193 (1): 265-275. | |
| |
10. Mazzoni I. E., Ledebur H. C. Jr., Paramithiotis E., Cashman N. Lymphoid signal transduction mechanisms linked to cellular prion protein. Biochem. Cell Biol, 2005; 83 (5): 644-653. | |
| |
11. Sahu N. K., Shilakari G., Nayak A., Kohli D. V. Antisense technology: a selective tool for gene expression regulation and gene targeting. Curr. Pharm. Biotechnol, 2007; 5: 291-304. | |
| |
12. Sakurai H., Kawabata K., Sakurai F. et al. Innate immune response induced by gene delivery vectors International. J. of Pharmaceutics, 2008; 354: 9-15. | |
| |
13. Supattapone S., Wille H., Uyechi L. et al. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol, 2001; 75(7):3453-3461. | |
| |
14. Weissmann C., Flechsig E. PrP knock-out and PrP transgenic mice in prion research. British Medical Bulletin, 2003; 66: 43-60. | |
| |
15. White M. D., Mallucci G. R. Therapy for prion diseases: Insights from the use of RNA interference. Prion, 2009; 3(3):121-8. |
Refbacks
- There are currently no refbacks.
Copyright (c) 2011 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.